Global Health Matters

Influenza Version vom 14.07.2006
29 April 2021 - By Thomas B. Cueni
This oped was originally published on International Business Times on 11 April 2021. Imagine if China had refused to share Covid-19's genetic sequences with other countries. Vaccine development would have been delayed indefinitely. Monitoring the virus would have been next to impossible. Thankfully, that didn't happen. Chinese scientists shared the ...
Read More
29 April 2021 - By Thomas B. Cueni
This oped was published on the Financial Times on 25 April 2021 1998, 39 pharmaceutical companies sued Nelson Mandela’s South African government to stop legislation that allowed pharmacists to substitute generic HIV/Aids drugs for brand-name ones. It was one of the dumbest things the industry ever did. What started as ...
Read More
29 April 2021 - By Thomas B. Cueni
On the first anniversary of the Access to COVID-19 Tools Accelerator (ACT Accelerator), high-level representatives – from pharma and biotech trade associations and vaccine manufacturers from both developed and developing countries – met to discuss the challenges of scaling-up vaccine production and ensuring vaccine equity. Present at the meeting were ...
Read More
21 April 2021 - By Greg Perry
On April 12 and 13 the African Union and the African CDC organized Africa’s Vaccine Manufacturing for Health Security virtual conference, opened by HE Moussa Faki Mahamat, Chairperson of the African Union Commission and chaired by HE Félix Antoine Tshilombo Tshisekedi, Chair of the African Union and President of the ...
Read More
14 April 2021 - By Thomas B. Cueni
I am honored to have been invited to speak on behalf of the innovative pharmaceutical industry at the launch of the new Global Diabetes Compact on 14 April 2021. The Global Diabetes Compact is being launched at an important time in history of diabetes. 100 years ago, the discovery of ...
Read More
14 April 2021 - By Thomas B. Cueni
On 9 April 2021, I participated in very lively debate hosted by Intelligence Squared, and moderated by John Donvan, Putlizer Prize Finalist and America's best recognized moderator of live event debate and four-time Emmy Award winner. I agreed to disagree with Brook Baker, Professor of Law, Northeastern University School of ...
Read More
Copyright: Aspen (Aspen Facility Port Elizabeth)
30 March 2021 - By Greg Perry
Increasing manufacturing capacity for COVID-19 vaccines is one of the biggest challenges we need to address in our common goal to bring this pandemic to an end. Science has delivered not one but several vaccines that are safe and effective and the goal is ensure fair and equitable delivery to ...
Read More
30 March 2021 - By Jean-Christophe Tellier
2020 witnessed a decade of scientific progress compressed into just 12 months. And as a result we now have, ahead of all predictions, a number of C-19 vaccines that can protect the heroic healthcare workers, the elderly and the vulnerable; and hopefully society as a whole as long as we ...
Read More
Coronavirus pandemic. Novel coronavirus (2019-nCoV), people in white medical face mask. Concept of coronavirus quarantine vector illustration. Seamless pattern.
24 March 2021 - By Thomas B. Cueni
This blog was originally published on Media Planet Infectious Disease campaign on 24 March 2021.  Whilst we are still in the midst of COVID-19, the worst pandemic since 1918 which is affecting every part of our lives, we can draw some lessons that will allow us to be better prepared ...
Read More
11 March 2021 - By Thomas B. Cueni
A summit was convened in a matter of weeks by Chatham House, in collaboration with COVAX, IFPMA, DCVMN, and BIO, took place on 8-9 March 2021. A discussion document helped inform participants, gave an overview of the current COVID-19 vaccine manufacturing supply chain and identified emerging challenges. While the meeting was conducted under Chatham ...
Read More
25 February 2021 - By James Anderson
Antibiotics have transformed healthcare. But today, the ubiquitous use of these live-saving drugs has led to the development of antibiotic-resistant bacteria. Once-treatable diseases like common infections of the bloodstream, urinary or respiratory tracts are becoming more difficult to treat using these tools. Combating drug resistance means facing a silent pandemic ...
Read More
23 February 2021 - By Thomas B. Cueni
This blog was originally posted on Pharma Boardroom on 23 February 2021 The story of COVID-19 vaccines is one of incredible collaboration. Never before has there been such an effort on a mass scale to solve a global health crisis. We've seen a decade of normal vaccine development compressed into ...
Read More
22 December 2020 - By Thomas B. Cueni
This oped was originally published on Media Planet Vaccine Awareness Campaign on 22 December 2020 Vaccines are one of the most cost effective interventions we have to safeguard public health and yet during this pandemic we have seen a decrease in public confidence. The latest World Economic Forum/Ipsos survey found ...
Read More
15 December 2020 - By Thomas B. Cueni
Last week, IFPMA hosted the fifth and last CEO COVID-19 media briefing of 2020 with CEOs and top executives from Eli Lilly and Company, Johnson & Johnson, Pfizer and Roche.  I joined the CEOs as they shared their take on progress achieved in 2020 and insights into 2021 and beyond. ...
Read More
9 December 2020 - By Laetitia Bigger
This oped was originally published on Media Planet Value of Vaccines Q4 2020 Campaign on 10 December 2020 The COVID-19 pandemic has reminded us how vulnerable the world is in the face of deadly pathogens. Vaccines have been an essential tool offering protection from diseases like diphtheria, tetanus, pneumonia, and ...
Read More
1 2 3 13